An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients

Journal of Cosmetic Dermatology

Volumn 5, Issue 1, 2006, Pages 23-29

  Draelos, Zoe Diana ^a,c   Green, Barbara A ^b   Edison, Brenda L ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NeoStrata Company Inc   (United States)

^c NONE   (United States)

Author keywords

Azelaic acid; Polyhydroxy acids; Rosacea

Indexed keywords

AZELAIC ACID; DERMATOLOGICAL AGENT; FINACEA; GLUCONOLACTONE; NEOSTRATA FACIAL CLEANSER; NEOSTRATA ULTRA MOISTURIZING CREAM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BURNING SENSATION; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DERMATOLOGY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; ROSACEA; SCORING SYSTEM; SENSORY DYSFUNCTION; SEX DIFFERENCE; SKIN CARE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; ERYTHEMA; FEMALE; GELS; HUMANS; INFLAMMATION; ROSACEA; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33645535316     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2006.00219.x     Document Type: Article

References (15)

1. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41.
2. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
3. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results for two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-45.
4. Bernstein EF, Green B, Edison B, Wildnauer R. Polyhydroxy acids (PHAs): clinical uses of the next generation of hydroxy acids. Skin Aging 2001; 9 (Suppl.): 4-11.
5. Grimes PE, Green BA, Wildnauer RH, Edison BL. The use of polyhydroxy acids (PHAs) in photoaged skin. Cutis 2004; 73 (Suppl. 2): 3-13.
6. Yu RJ, Van Scott EJ. Bioavailability of alpha-hydroxy acids in topical formulations. Cosmet Dermatol 1996; 9 (6): 54-62.
7. Hunt MJ, Barnetson R Stc. C. A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australas J Dermatol 1992; 33: 131-4.
8. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994; 130: 359-62.
9. Van Scott EJ, Yu RJ. Action of alpha-hydroxy acids on skin compartments. J Geriat Dermatol 1995; 3 (Suppl. A): 19A-24A.
10. Ditre CM, Griffin TD, Murphy GF, et al. Effects of alpha hydroxyacids on photoaged skin: A pilot clinical, histologic and ultrastructural study. J Am Acad Dermatol 1996; 34: 187 -95.
11. Berardesca E, Distante F, Vignoli GP, Oresajo C, Green B. Alpha hydroxyacids modulate stratum corneum barrier function. Br J Dermatol 1997; 137: 934-8.
12. Edison BL, Green BA, Wildnauer RH, Sigler ML. A polyhydroxy acid skin care regimen provides antiaging effects comparable to an alpha-hydroxy acid regimen. Cutis 2004; 73 (Suppl. 2): 14-7.
13. Outwater S, Kohut BE, Greenspan AH, Edison BL, Ciociola A. An evaluation of the exfoliation efficacy of skin care formulations containing the polyhydroxy acid, gluconolactone. Skin Aging 2001; 9 (Suppl.): 26-30.
14. Bergfeld WF, Remzi BK, Green B, Patel P, Ravas R. An evaluation of the gluconolactone sensitive skin care products. Am Acad Dermatol Poster Exhibit, Orlando February 1998.
15. Rizer R, Turcott A, Edison B, et al. An evaluation of the tolerance profile of gluconolactone-containing skin care fomulations in individuals with rosacea. Skin Aging 2001; 9 (Suppl.): 22-5.